Xenon Pharmaceuticals Inc. - Common Shares (XENE) Covered Calls
You can sell covered calls on Xenon Pharmaceuticals Inc. - Common Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for XENE (prices last updated Fri 4:16 PM ET):
| Xenon Pharmaceuticals Inc. - Common Shares (XENE) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 38.63 | -0.27 | 27.99 | 42.00 | 838K | - | 3.0 |
| Covered Calls For Xenon Pharmaceuticals Inc. - Common Shares (XENE) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Jan 17 | 37.5 | 0.70 | 41.30 | -9.2% | -115.8% | |
| Feb 21 | 37.5 | 1.50 | 40.50 | -7.4% | -42.2% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
| Top 10 Open Interest For Jan 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | INTC covered calls | 1. | RGTI covered calls | |
| 2. | SLV covered calls | 7. | SPY covered calls | 2. | NMRA covered calls | |
| 3. | AAPL covered calls | 8. | TSLA covered calls | 3. | HUMA covered calls | |
| 4. | EEM covered calls | 9. | IWM covered calls | 4. | DLO covered calls | |
| 5. | XLF covered calls | 10. | TLT covered calls | 5. | MARA covered calls | |
Want more examples? XEL Covered Calls | XERS Covered Calls
